Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Pipeline
Cancer Program
Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Recent Posts
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
AUSBIZ | Interview with Dr Chris Burns
Phase 1B of ACCENT Trial in Pancreatic Cancer Complete
VIDEO | The Market Herald
Archives
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 2022
April 2022
Categories
Company News
Media
Uncategorized
Videos
August 2nd, 2023
ACCENT Trial Recruitment Update
Read More
January 11th, 2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Read More
June 29th, 2022
The science of manufacturing, at scale
Read More
March 17th, 2022
Scientific rigour is in our DNA
Read More
October 7th, 2021
MEET THE TEAM | Dr John Lambert, CEO
Read More
October 4th, 2021
VIDEO | Science Advances paper discussed on Proactive
Read More
September 30th, 2021
VIDEO | Amplia featured on Channel 9 News
Read More
September 30th, 2021
BioMelbourne Network | Breakthrough research on pancreatic cancer
Read More
September 22nd, 2021
Bioshares | Amplia Therapeutics to Start Two Phase II Studies in 2022
Read More
June 2nd, 2021
Positive data sends Amplia Therapeutics nearly 50 per cent up
Read More
March 18th, 2021
Amplia Therapeutics signs agreement with Garvan Institute
Read More
March 17th, 2021
Amplia Therapeutics completes single-dose study of AMP945
Read More
October 14th, 2020
Joint Cancer Therapeutics CRC/AMPLIA Therapeutics Press Release
Read More
1
